CoChat

The prevention and treatment of Plasmodium vivax malaria

Chu, Cindy S., White, Nicholas J. · 2021 · PLOS Medicine
Cited by 88

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1003561

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 116

  1. PW Gething, 2011, Modelling the global constraints of temperature on transmission of Plasmodium falciparum and Plasmodium vivax, Parasit Vectors, 4, 92, 10.1186/1756-3305-4-92 · DOI · Paper page
  2. VA Mironova, 2020, Re-introduction of vivax malaria in a temperate area (Moscow region, Russia): A geographic investigation, Malar J, 19, 1, 10.1186/s12936-020-03187-8 · doi:10.1186/s12936-020-03187-8
  3. RE Howes, 2016, Global Epidemiology of Plasmodium vivax, Am J Trop Med Hyg, 95, 15, 10.4269/ajtmh.16-0141 · DOI · Paper page
  4. KH Rieckmann, 1989, Plasmodium vivax resistance to chloroquine?, Lancet, 2, 1183, 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
  5. M Whitby, 1989, Chloroquine resistant Plasmodium vivax, Lancet, 334, 1395, 10.1016/S0140-6736(89)92002-3 · doi:10.1016/s0140-6736(89)92002-3
  6. DK Kochar, 2014, A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India, J Vector Borne Dis, 51, 200, 10.4103/0972-9062.141760 · DOI
  7. B Genton, 2008, Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea, PLoS Med, 5, e127, 10.1371/journal.pmed.0050127 · DOI · Paper page
  8. EFC Lança, 2012, Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the Brazilian Amazon, PLoS ONE, 7, e35406, 10.1371/journal.pone.0035406 · DOI
  9. AM Quispe, 2014, Plasmodium vivax hospitalizations in a monoendemic malaria region: Severe vivax malaria?, Am J Trop Med Hyg, 91, 11, 10.4269/ajtmh.12-0610 · DOI
  10. VB Kute, 2012, Plasmodium vivax malaria-associated acute kidney injury, India, 2010–2011, Emerg Infect Dis, 18, 842, 10.3201/eid1805.111442 · DOI
  11. World Health Organization, 2014, Severe Malaria, Trop Med Int Health, 19, 7, 10.1111/tmi.12313_2 · DOI · Paper page
  12. KA Moore, 2017, Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: Observational data analysis, BMC Med, 15, 1, 10.1186/s12916-017-0863-z · DOI · Paper page
  13. P van den Eede, 2011, Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study, PLoS ONE, 6, e16257, 10.1371/journal.pone.0016257 · DOI
  14. A Daher, 2019, Evaluation of Plasmodium vivax malaria recurrence in Brazil, Malar J, 18, 1, 10.1186/s12936-019-2644-y · DOI
  15. JR Poespoprodjo, 2009, Vivax malaria: a major cause of morbidity in early infancy, Clin Infect Dis, 48, 1704, 10.1086/599041 · DOI · Paper page
  16. RJ Commons, 2019, The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis, BMC Med, 17, 151, 10.1186/s12916-019-1386-6 · DOI · Paper page
  17. MF Boyd, 1934, Observations on naturally induced malaria, South Med J, 27, 155, 10.1097/00007611-193402000-00011 · doi:10.1097/00007611-193402000-00011
  18. EA Ashley, 2009, Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria, Malar J., 8, 241, 10.1186/1475-2875-8-241 · DOI · Paper page
  19. J Maltha, 2010, Malaria rapid diagnostic tests: Plasmodium falciparum infections with high parasite densities may generate false positive Plasmodium vivax pLDH lines, Malar J, 9, 1, 10.1186/1475-2875-9-198 · DOI
  20. J Cunningham, 2019, A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): Performance, procurement and policy, Malar J, 18
  21. M Imwong, 2014, High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias, J Clin Microbiol, 52, 3303, 10.1128/JCM.01057-14 · DOI · Paper page
  22. NJ White, 2014, Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria, Malar J, 13
  23. AR Taylor, 2019, Resolving the cause of recurrent Plasmodium vivax malaria probabilistically, Nat Commun, 10, 5595, 10.1038/s41467-019-13412-x · DOI · Paper page
  24. M Imwong, 2012, The first Plasmodium vivax relapses of life are usually genetically homologous, J Infect Dis, 205, 680, 10.1093/infdis/jir806 · DOI · Paper page
  25. M Imwong, 2007, Relapses of Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites, J Infect Dis, 195, 927, 10.1086/512241 · DOI · Paper page
  26. T Stewart, 2003, Factors that affect the success and failure of insecticide treated net programs for malaria control in SE Asia and the Western Pacific
  27. FM Smithuis, 2013, The effect of insecticide-treated bed nets on the incidence and prevalence of malaria in children in an area of unstable seasonal transmission in western Myanmar, Malar J, 12
  28. N Kwansomboon, 2017, Vector bionomics and malaria transmission along the Thailand-Myanmar border: a baseline entomologic survey, J Vector Biol, 424, 84, 10.1111/jvec.12242 · DOI
  29. EK Thomsen, 2017, Mosquito behavior change after distribution of bednets results in decreased protection against malaria exposure, J Infect Dis, 215, 790
  30. MT White, 2018, Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax, Nat Commun, 9, 1, 10.1038/s41467-018-05860-8 · DOI
  31. K Bayili, 2017, Evaluation of efficacy of Interceptor® G2, a long-lasting insecticide net coated with a mixture of chlorfenapyr and alpha-cypermethrin, against pyrethroid resistant Anopheles gambiae s.l. in Burkina Faso, Malar J, 16, 1, 10.1186/s12936-017-1846-4 · DOI
  32. C Ngufor, 2017, Which intervention is better for malaria vector control: Insecticide mixture long-lasting insecticidal nets or standard pyrethroid nets combined with indoor residual spraying?, Malar J, 16, 1, 10.1186/s12936-017-1987-5 · DOI · Paper page
  33. N Protopopoff, 2018, Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two fact, Lancet, 391, 1577, 10.1016/S0140-6736(18)30427-6 · DOI · Paper page
  34. H van den Berg, 2012, Global Trends in the Use of Insecticides to Control Vector-Borne Diseases, Environ Health Perspect, 120, 577, 10.1289/ehp.1104340 · DOI · Paper page
  35. J Mouchet, 1988, Agriculture and Vector Resistance, Int J Trop Insect Sci, 9, 297, 10.1017/S1742758400006238 · DOI · Paper page
  36. W van Bortel, 2008, The insecticide resistance status of malaria vectors in the Mekong region, Malar J, 7, 1, 10.1186/1475-2875-7-102 · DOI · Paper page
  37. SL Hoffman, 2015, The March Toward Malaria Vaccines, Am J Prev Med, 49, S319, 10.1016/j.amepre.2015.09.011 · DOI · Paper page
  38. S Herrera, 2011, Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51, Am J Trop Med Hyg, 84, 12, 10.4269/ajtmh.2011.09-0516 · DOI
  39. JW Bennett, 2016, Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy, PLoS Negl Trop Dis, 10, e0004423, 10.1371/journal.pntd.0004423 · doi:10.1371/journal.pntd.0004423
  40. RO Payne, 2017, Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies, JCI Insight, 2, 1, 10.1172/jci.insight.93683 · DOI
  41. EM Malkin, 2005, Phase 1 vaccine trial of Pvs25H: A transmission blocking vaccine for Plasmodium vivax malaria, Vaccine, 23, 3131, 10.1016/j.vaccine.2004.12.019 · DOI · Paper page
  42. Y Wu, 2008, Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs 25 formulated with montanide ISA 51, PLoS ONE, 3
  43. WH Tham, 2017, Plasmodium vivax vaccine research–we’ve only just begun, Int J Parasitol, 47, 111, 10.1016/j.ijpara.2016.09.006 · DOI
  44. World Health Organization, 2015, Guidelines for the treatment of malaria
  45. R Ahmed, 2019, Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin–piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-la, Lancet Infect Dis, 19, 973, 10.1016/S1473-3099(19)30156-2 · DOI · Paper page
  46. E Meltzer, 2018, Vivax malaria chemoprophylaxis: the role of atovaquone-proguanil compared to other options, Clin Infect Dis, 66, 1751, 10.1093/cid/cix1077 · doi:10.1093/cid/cix1077
  47. SA Mikolajczak, 2015, Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice, Cell Host Microbe, 17, 526, 10.1016/j.chom.2015.02.011 · DOI · Paper page
  48. ME Gilder, 2018, Primaquine pharmacokinetics in lactating women and breastfed infant exposures, Clin Infect Dis, 67, 1000, 10.1093/cid/ciy235 · DOI
  49. JK Baird, 2020, Evaluation of the efficacy and safety of tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure (anti-relapse) of Plasmodium vivax malaria in Indonesia—INSPECTOR study, In ASTMH Annual Meeting
  50. ID Velez, 2020, A randomized, open-label, non-comparative multicenter study to assess the pharmacokinetics, safety, and efficacy of tafenoquine in the treatment of pediatric subjects with Plasmodium vivax malaria (TEACH study), ASTMH Annual Meeting
  51. JC Haston, 2019, Guidance for using tafenoquine for prevention and antirelapse therapy for malaria—United States, 2019, MMWR Morb Mortal Wkly Rep, 68, 1062, 10.15585/mmwr.mm6846a4 · DOI · Paper page
  52. NJ White, 1988, Chloroquine Treatment of Severe Malaria in Children, N Engl J Med, 319, 1493, 10.1056/NEJM198812083192301 · doi:10.1056/nejm198812083192301
  53. J Maguire, 2006, Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia, Clin Infect Dis, 2197, 1067, 10.1086/501357 · doi:10.1086/501357
  54. A Ratcliff, 2007, Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison, Lancet, 369, 757, 10.1016/S0140-6736(07)60160-3 · DOI · Paper page
  55. A Daher, 2018, Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: An open label randomized clinical trial RBR-79s56s RBR, Malar J, 17, 1, 10.1186/s12936-018-2192-x · doi:10.1186/s12936-018-2192-x
  56. MJ Grigg, 2016, Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial, Clin Infect Dis, 62, 1403, 10.1093/cid/ciw121 · DOI
  57. AP Phyo, 2011, Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial, Clin Infect Dis, 53, 977, 10.1093/cid/cir631 · DOI · Paper page
  58. F Smithuis, 2010, Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial, Lancet Infect Dis, 10, 673, 10.1016/S1473-3099(10)70187-0 · DOI · Paper page
  59. MM Fukuda, 2017, A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria, PLoS ONE, 12, e0187376, 10.1371/journal.pone.0187376 · doi:10.1371/journal.pone.0187376
  60. S Pukrittayakamee, 1994, Blood Stage Antimalarial Efficacy of Primaquine in Plasmodium vivax Malaria, J Infect Dis, 169, 932, 10.1093/infdis/169.4.932 · DOI
  61. S Pukrittayakamee, 2008, Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria, Am J Trop Med Hyg, 79, 378, 10.4269/ajtmh.2008.79.378 · DOI
  62. JK Baird, 1997, Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels, Am J Trop Med Hyg, 56, 621, 10.4269/ajtmh.1997.56.621 · DOI · Paper page
  63. AR Hasugian, 2007, Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax Malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
  64. AP Pasaribu, 2013, A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia, J Infect Dis, 208, 1906, 10.1093/infdis/jit407 · DOI
  65. K Saravu, 2016, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in Southwestern India, PLoS ONE, 11, e0157666, 10.1371/journal.pone.0157666 · DOI · Paper page
  66. CS Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
  67. T Shumbej, 2019, Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia, BMC Infect Dis, 19, 4, 10.1186/s12879-019-4055-7 · DOI · Paper page
  68. E Mesa-Echeverry, 2019, Chloroquine–primaquine therapeutic efficacy, safety, and plasma levels in patients with uncomplicated Plasmodium vivax malaria in a Colombian Pacific region, Am J Trop Med Hyg, 100, 72, 10.4269/ajtmh.18-0655 · DOI · Paper page
  69. KR Rijal, 2019, Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal, J Infect Dis, 220, 448, 10.1093/infdis/jiz126 · DOI · Paper page
  70. MR Costa, 2007, Chloroquine-resistant Plasmodium vivax, Brazilian Amazon, Emerg Infect Dis, 13, 7
  71. A Añez, 2015, Resistance of infection by Plasmodium vivax to chloroquine in Bolivia, Malar J, 14, 261, 10.1186/s12936-015-0774-4 · DOI
  72. S Xu, 2020, Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial, Travel Med Infect Dis, 36, 101499, 10.1016/j.tmaid.2019.101499 · DOI · Paper page
  73. B Russell, 2008, Determinants of in vitro drug susceptibility testing of Plasmodium vivax, Antimicrob Agents Chemother, 52, 1040, 10.1128/AAC.01334-07 · DOI · Paper page
  74. M Imwong, 2002, Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates, Antimicrob Agents Chemother, 46, 1161, 10.1128/AAC.46.4.1161-1161.2002 · doi:10.1128/aac.46.4.1161-1161.2002
  75. DN Hupalo, 2016, Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax, Nat Genet, 48, 953, 10.1038/ng.3588 · DOI · Paper page
  76. NJ White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
  77. J Recht, 2018, Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries, PLoS Negl Trop Dis, 12, e0006230, 10.1371/journal.pntd.0006230 · DOI · Paper page
  78. EC Duarte, 2001, Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria, Am J Trop Med Hyg, 65, 471, 10.4269/ajtmh.2001.65.471 · doi:10.4269/ajtmh.2001.65.471
  79. RSU da Silva, 2003, Esquemas terapêuticos encurtados para o tratamento de malária por Plasmodium vivax, Rev Soc Bras Med Trop, 36, 235, 10.1590/S0037-86822003000200007 · doi:10.1590/s0037-86822003000200007
  80. S Negreiros, 2016, Efficacy of chloroquine and primaquine for the treatment of uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, Am J Trop Med Hyg, 95, 1061, 10.4269/ajtmh.16-0075 · DOI · Paper page
  81. S Ladeia-Andrade, 2019, Monitoring the efficacy of chloroquine-primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil, Antimicrob Agents Chemother, 63, e01965, 10.1128/AAC.01965-18 · DOI · Paper page
  82. J Carmona-Fonseca, 2009, Prevention of Plasmodium vivax malaria recurrence: Efficacy of the standard total dose of primaquine administered over 3 days, Acta Trop, 112, 188, 10.1016/j.actatropica.2009.07.024 · DOI
  83. JK Baird, 1997, Whole Blood Chloroquine Concentrations with Plasmodium vivax Infection in Irian Jaya, Indonesia, Am J Trop Med Hyg, 56, 618, 10.4269/ajtmh.1997.56.618 · doi:10.4269/ajtmh.1997.56.618
  84. CS Chu, 2018, Chloroquine versus dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria, Clin Infect Dis, 68, 1311, 10.1093/cid/ciy735 · DOI
  85. WRJ Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial, Lancet, 394, 929, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
  86. J Arnold, 1954, The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria, J Lab Clin Med, 44, 429
  87. T Leslie, 2008, A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan, PLoS ONE, 3, e2861, 10.1371/journal.pone.0002861 · DOI
  88. S Kheng, 2015, Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency, BMC Med, 13, 203, 10.1186/s12916-015-0441-1 · DOI
  89. AS Alving, 1955, Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine, J Lab Clin Med, 46, 301
  90. JW Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria, N Engl J Med, 369, 1380, 10.1056/NEJMc1301936 · DOI · Paper page
  91. BS Pybus, 2013, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6, Malar J, 12, 212, 10.1186/1475-2875-12-212 · DOI · Paper page
  92. RE Howes, 2013, Spatial distribution of G6PD deficiency variants across malaria-endemic regions, Malar J, 12, 418, 10.1186/1475-2875-12-418 · DOI · Paper page
  93. RS Hockwald, 1952, Toxicitiy of primaquine in negroes, JAMA, 149, 1568, 10.1001/jama.1952.72930340027010c · doi:10.1001/jama.1952.72930340027010c
  94. R Rueangweerayut, 2017, Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers, Am J Trop Med Hyg, 97, 702, 10.4269/ajtmh.16-0779 · DOI · Paper page
  95. E Beutler, 1954, The hemolytic effect of primaquine IV. The relationship of cell age to hemolysis, J Lab Clin Med, 44, 439
  96. A Minucci, 2012, Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations, Blood Cells Mol Dis, 48, 154, 10.1016/j.bcmd.2012.01.001 · doi:10.1016/j.bcmd.2012.01.001
  97. K Thriemer, 2020, The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia, PLoS Negl Trop Dis, 79, 1
  98. T Leslie, 2010, The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan, PLoS Med, 7, e1000283, 10.1371/journal.pmed.1000283 · DOI · Paper page
  99. GR Awab, 2021, Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria, Elife, 10, e62448, 10.7554/eLife.62448 · DOI
  100. J Recht, 2014, World Health Organization
  101. WM Monteiro, 2016, Fatal primaquine-induced hemolysis in a patient with Plasmodium vivax malaria and G6PD A- variant in the Brazilian Amazon, Clin Infect Dis, 62, 1188, 10.1093/cid/ciw039 · DOI · Paper page
  102. JA Green, 2014, Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects, J Clin Pharmacol, 54, 995, 10.1002/jcph.302 · doi:10.1002/jcph.302
  103. S Warrasak, 2018, Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure., Int Ophthalmol, 39, 1767, 10.1007/s10792-018-1003-2 · DOI
  104. J Ackert, 2019, Randomized placebo-controlled trial evaluating the ophthalmic safety of single-dose tafenoquine in healthy volunteers, Drug Saf, 42, 1103, 10.1007/s40264-019-00839-w · DOI
  105. S Duparc, 2020, Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review, Malar J, 19, 1, 10.1186/s12936-020-03184-x · DOI
  106. A Llanos-Cuentas, 2019, Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 229, 10.1056/NEJMoa1802537 · DOI · Paper page
  107. MVG Lacerda, 2019, Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria, N Engl J Med, 380, 215, 10.1056/NEJMoa1710775 · DOI · Paper page
  108. NJ White, 2021, Anti-malarial drug effects on parasite dynamics in vivax malaria, Malar J, 20, e161, 10.1186/s12936-021-03700-7 · DOI
  109. PL St Jean, 2016, Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial, Malar J, 15, 97, 10.1186/s12936-016-1145-5 · DOI
  110. S Pal, 2018, Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient, Am J Trop Med Hyg, 100, 213, 10.4269/ajtmh.18-0612 · DOI · Paper page
  111. NH Fairley, 1947, Sidelights on malaria in man obtained by subinoculation experiments, Trans R Soc Trop Med Hyg, 40, 621, 10.1016/0035-9203(47)90025-4 · DOI
  112. JS McCarthy, 2019, Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, nonimmune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blind, placebo-controlled Phase 1b study, Clin Infect Dis, 69, 480, 10.1093/cid/ciy939 · doi:10.1093/cid/ciy939
  113. NJ White, 2002, The assessment of antimalarial drug efficacy, Trends Parasitol, 18, 458, 10.1016/S1471-4922(02)02373-5 · DOI · Paper page
  114. L von Seidlein, 2019, The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in southeast Asia: A cluster randomised trial, PLoS Med, 16, 1, 10.1371/journal.pmed.1002745 · DOI · Paper page
  115. MS Hsiang, 2013, Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China, Malar J, 12, 383, 10.1186/1475-2875-12-383 · DOI
  116. RM Garfield, 1983, Changes in malaria incidence after mass drug administration in Nicaragua, Lancet, 322, 500, 10.1016/S0140-6736(83)90523-8 · DOI

Cited by

See all 88

Metadata

Authors
Chu, C. S., & White, N. J.
Venue
PLOS Medicine
Published
2021-04-23
Volume
18
Issue
4
Pages
e1003561
ISSN
1549-1676
Cited by
88
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.